The European Commission has authorised Novo Nordisk's Frehemgo (denecimig) to prevent bleeding in adults and children with haemophilia A, with or without inhibitors, Novo announced on 13 November 2026. The injection under the skin can be given monthly, every two weeks or weekly from a pre-filled pen. Its pivotal trial included two Dublin sites.
The approval follows a positive opinion from the European Medicines Agency's CHMP on 17 September 2026. Novo plans to launch Frehemgo in the first European countries in the year ahead. Irish availability depends on a separate HSE reimbursement decision, and no assessment is listed yet by the National Centre for Pharmacoeconomics.
- Decision: EU marketing authorisation for Frehemgo (denecimig) for routine prophylaxis of bleeding in haemophilia A, announced by Novo Nordisk on 13 November 2026.
- Who it covers: adults and children with haemophilia A, with or without factor VIII inhibitors. EMA says it can be used in all age groups.
- Dosing: a choice of once monthly, once every two weeks or once weekly, by injection under the skin from a single-use pre-filled pen.
- Evidence: the FRONTIER programme. In the pivotal FRONTIER2 trial, published in the New England Journal of Medicine, Novo says bleeding rates fell significantly against prior factor prophylaxis and on-demand treatment.
- Ireland: FRONTIER2 listed sites at St James's and CHI Crumlin in Dublin. Reimbursement in Ireland would need an HSE decision informed by the NCPE.
What has the EU approved?
Novo's release says the European Commission granted marketing authorisation for Frehemgo "for haemophilia A (congenital FVIII deficiency), with or without inhibitors, in adults and children." The use is routine prophylaxis, meaning regular treatment to prevent or reduce the frequency of bleeding episodes. Frehemgo is not described as a treatment for bleeds once they start.
The CHMP opinion on EMA's website gives more detail. It covers patients with factor VIII inhibitors, and patients without inhibitors who have severe disease (factor VIII below 1%) or moderate disease (factor VIII from 1% to 5%) that needs prophylaxis. When we checked on 14 November, EMA's page still showed the opinion and had not yet been updated with the Commission decision, and Novo's release does not give the date of the decision itself.
Haemophilia A is an inherited bleeding disorder in which the blood lacks enough clotting factor VIII. Novo's release says up to 30% of people with severe haemophilia A develop inhibitors, antibodies that make factor VIII replacement less effective.
How does denecimig work?
Denecimig, developed as Mim8, is a bispecific antibody that Novo describes as a factor VIIIa mimetic. It binds two clotting proteins at once, factor IXa and factor X. Novo says it "'mimics' the role of FVIIIa by bridging Factor IXa and Factor X", standing in for the missing factor VIII in the clotting process.
One of the Frehemgo trials, FRONTIER5, tested switching directly from emicizumab, an existing antibody medicine used for haemophilia A prophylaxis. Our pages on denecimig and emicizumab list the current trials for both medicines.
What did the FRONTIER trials show?
Novo's release describes four trials in the FRONTIER programme. It gives the design of each but does not give the bleeding rate figures in the release itself. The FRONTIER2 results are published in the New England Journal of Medicine (2026;394:1696-1709), so the pivotal data are peer reviewed.
| Trial | What it tested |
|---|---|
| FRONTIER2 (NCT05053139), phase 3, 281 enrolled | Pivotal trial in people aged 12 and over; monthly and weekly dosing; significantly lower bleeding rates than prior factor prophylaxis and on-demand treatment |
| FRONTIER3 (NCT05306418), phase 3, 70 enrolled | Children under 12; monthly and weekly dosing; results consistent with adolescents and adults |
| FRONTIER4 (NCT05685238), phase 3, 451 enrolled | Open-label extension; every two weeks dosing and long-term safety across all regimens |
| FRONTIER5 (NCT05878938), phase 3, 61 enrolled | Direct switch from emicizumab; no new safety signals reported by Novo |
On side effects, EMA's summary says: "The most common side effects with Frehemgo are injection site reactions, prothrombin fragment 1.2 increased and fibrin D dimer increased." The last two are laboratory markers of clotting activity. For FRONTIER5, Novo says thrombin generation rose into the normal range without levels that might pose a risk of blood clots.
Martin Holst Lange, Chief Scientific Officer and Executive Vice President of Research and Development at Novo Nordisk, said the approval "reflects the strength and consistency of the FRONTIER programme". Maria Elisa Mancuso, Medical Member of the Board of Directors of the World Federation of Hemophilia, said: "Living with haemophilia means constantly planning around the risk of bleeding, often from early childhood."
Did the trials run in Ireland?
Yes. The ClinicalTrials.gov record for FRONTIER2 lists two Irish sites, both in Dublin: St James's CRF and CHI Crumlin Haematology. The FRONTIER4 extension lists St James's CRF. FRONTIER2 ran at 163 sites in total, with EU sites in countries including France, Belgium, the Netherlands, Portugal, Romania and Slovakia, and four sites in the United Kingdom.
This means Irish clinicians and patients helped generate the evidence behind the EU decision. It does not mean the medicine is available in Ireland. Our list of haemophilia A trials in Ireland shows current studies.
When could Frehemgo reach Irish patients?
That is not known. An EU authorisation is valid in every member state, including Ireland, but each country decides on price and reimbursement. In Ireland, the HSE Corporate Pharmaceutical Unit commissions the National Centre for Pharmacoeconomics (NCPE) to assess new medicines. The NCPE carries out a rapid review and then advises whether a full health technology assessment is needed. The HSE makes the final decision, taking account of the Health (Pricing and Supply of Medical Goods) Act 2013.
The NCPE website shows no entry for denecimig or Frehemgo at the time of writing. Novo has not named the countries where it will launch first. Our guide to rare disease drug companies covers the wider field. People with haemophilia should not change their treatment without talking to their haematology team or pharmacist.
Frequently asked questions
What is Frehemgo?
Frehemgo is the brand name of denecimig, a bispecific antibody from Novo Nordisk that mimics activated factor VIII. It is used to prevent bleeding in haemophilia A.
Can it be used by people with inhibitors?
Yes. The EU indication covers haemophilia A with or without factor VIII inhibitors, in adults and children.
How often is it given?
Once monthly, once every two weeks or once weekly, as an injection under the skin from a pre-filled pen, according to Novo.
Is it approved in the US?
Not yet. Novo says it is under review by the FDA and other regulators. Saudi Arabia has approved it.
Is it available in Ireland?
Not yet known. It needs an HSE reimbursement decision, and no NCPE assessment is listed at the time of writing.
Outlook
The next milestones are EMA's publication of the full product information, the first European launches and the US review. In Ireland, the key question is whether Novo applies for reimbursement and how the NCPE assesses a new option alongside existing prophylaxis. Priya Life Science will report when an NCPE entry appears.
Sources
- Novo Nordisk via GlobeNewswire (republished by Yahoo Finance UK), FREHEMGO (denecimig) approved in the EU for haemophilia A, with a choice of monthly, every-two-weeks or weekly dosing, 13 November 2026
- Novo Nordisk, CHMP recommends EU approval of FREHEMGO (denecimig) for the treatment of haemophilia A, 17 September 2026
- European Medicines Agency, Frehemgo: opinion and medicine overview, accessed 14 November 2026
- ClinicalTrials.gov, A Research Study Investigating Mim8 in Adults and Adolescents With Haemophilia A With or Without Inhibitors (FRONTIER2), NCT05053139, accessed 14 November 2026
- ClinicalTrials.gov, A Research Study Looking at Mim8 in Children With Haemophilia A With or Without Inhibitors (FRONTIER3), NCT05306418, accessed 14 November 2026
- ClinicalTrials.gov, A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia A (FRONTIER4), NCT05685238, accessed 14 November 2026
- ClinicalTrials.gov, A Research Study Looking at How Safe it is to Switch From Emicizumab to Mim8 (FRONTIER5), NCT05878938, accessed 14 November 2026
- National Centre for Pharmacoeconomics, Submission process, accessed 14 November 2026
COVER_CREDIT
Cover image: AI-generated illustration.